These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10319915)

  • 1. WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood.
    Carlson R; Kreft A; Hartman D; Tomchek L; Lock Y; Weichman B; Glaser K
    Prostaglandins Leukot Essent Fatty Acids; 1999 Jan; 60(1):31-41. PubMed ID: 10319915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
    Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues.
    Heaslip RJ; Grimes D; Berkenkopf JW; Ilsemann BA; Sickels BD; Weichman BM
    Eur J Pharmacol; 1993 Apr; 234(2-3):247-54. PubMed ID: 8482329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WY-50, 295 tromethamine: an orally active 5-lipoxygenase inhibitor with anti-allergic activity.
    Weichman BM; Berkenkopf JW; Chang JY; Heaslip RJ; Kreft AF; Lewis AJ; Musser JH; Grimes D
    Agents Actions Suppl; 1991; 34():201-9. PubMed ID: 1793064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
    Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs.
    Howell RE; Sickels BD; Woeppel SL; Jenkins LP; Rubin EB; Weichman BM
    J Pharmacol Exp Ther; 1994 Jan; 268(1):353-8. PubMed ID: 8301576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
    Smith WG; Shaffer AF; Currie JL; Thompson JM; Kim S; Rao T; Isakson PC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1332-8. PubMed ID: 8531100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
    Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
    Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WY-50,295 tromethamine: a novel inhibitor of leukotriene-mediated reactions.
    Weichman BM; Berkenkopf JW; Grimes D; Heaslip RJ; Sturm RJ; Chang JY
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():477-80. PubMed ID: 1847784
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
    J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugs.
    Kreft AF; Failli AA; Musser JH; Kubrak DM; Banker AL; Steffan R; Demerson CA; Nelson JA; Shah US; Gray W
    Drugs Exp Clin Res; 1991; 17(8):381-7. PubMed ID: 1822830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-78773: a selective, potent 5-lipoxygenase inhibitor.
    Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
    J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
    Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
    J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
    Gillard J; Ford-Hutchinson AW; Chan C; Charleson S; Denis D; Foster A; Fortin R; Leger S; McFarlane CS; Morton H
    Can J Physiol Pharmacol; 1989 May; 67(5):456-64. PubMed ID: 2548691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-dependent eicosanoid metabolism by concanavalin A-stimulated human monocytes in vitro. Synergism with phorbol ester indicates separate regulation of leukotriene B4 synthesis and release.
    Hoffman T; Brando C; Lizzio EF; Lee YL; Hansen M; Tripathi AK; Taplits M; Puri J; Bonvini E; Abrahamsen TG
    J Immunol; 1991 Jan; 146(2):692-700. PubMed ID: 1846160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
    Cunningham FM; Andrews M; Landoni MF; Lees P
    J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
    Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW
    J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.